Global Asthma & COPD Drugs Market By Disease (Asthma, Chronic Obstructive Pulmonary Disease), By Medication Class(Long term asthma control medications, Quick Relief medications), By Route of Administration (Oral, Inhaled), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Report Overview

The Global Asthma & COPD Drugs Market size is expected to be worth around USD 64.6 Billion by 2033, from USD 38.2 Billion in 2023, growing at a CAGR of 5.6% during the forecast period from 2024 to 2033.

Asthma is a chronic inflammatory lung condition which affects airways which is not contagious. When the airways responses hyperly it leads to recurrent wheezing, chest tightness, coughing bouts and dyspnea. The biggest factor triggering asthma is allergy, but still is treatable as compared to other obstructive lung illnesses.

On the other hand, chronic obstructive pulmonary disease (COPD) results in restriction of airflow, which is not entirely curable. COPD is further categorized into emphysema, a complicated lung illness marked by destruction of alveoli and chronic bronchitis, which includes persistent inflammation of lower respiratory tract. Tobacco usage is the primary root cause of chronic obstructive pulmonary disease followed by passive smoking, ambient air pollution and occupational exposure.

The market for asthma and COPD drugs is majorly driven by combination of factors including rising geriatric population, advancing technologies and high prevalence of asthma and chronic obstructive pulmonary disease across the globe.

• According to World Health Organization’s 2021 Dataset, COPD is the third most common risk factor for death globally, with approximately 3.23 million fatality rate in 2019.
• According to Asthma and Allergy foundation of America report published in June 2019, 1 in every 13 Americans suffer from asthma. In addition, more than 11.4 million individuals dealing with asthma suffered with atleast one attack in 2017.
• According to World Ageing 2020 forecast, there were around 727 million individuals who were 65 or older in 2020 and is expected to reach 1.5 billion by 2050

Key Takeaways

• Based on disease type, the global asthma and COPD drugs market is led by asthma segment capturing a prominent market share in 2023.
• Based on class of medication, long term asthma control medication segment dominated the market grabbing a large market share of 71.4%
• Based on route of administration, oral medications is highly prescribed for asthmatic childrens.
• Based on distribution channel, retail pharmacies is at the forefront of global asthma and COPD drugs market in recent years.

Disease Type Analysis

Based on type of disease, the asthma and COPD drugs market is broadly categorized into Asthma and Chronic Obstructive Pulmonary Disease segments. Asthma segment came up as a frontrunner in the global asthma and COPD drugs market accounting a praiseworthy market revenue share of 61.2% in the year 2023.

This dominance is by virtue of asthma being a common life-threatening disease across the globe. The disease especially occur in children, where inhaled medications and drugs helps to manage the symptoms of asthma leading to a healthy life.

• According to World health Organization in 2019, an estimated 263 million individuals afflicted with asthma, resulting in 46,1000 motality rates.

COPD on the other hand, is the fastest growing segment owing to escalating air pollution and emission of toxic gases across the world.

• According to Institite of Health Metrics and Evaluation’s Global Burden of Disease Study (2016), there were around 215 million of COPD cases across the globe.

Medication Class Analysis

Based on medication class, the market fragments into long term asthma control medications and quick relief medications. The sub-segmentation of long term asthma control medication results into combination drugs, anticholinergics, inhaled corticosteroids, long-acting beta agonists, theophylline, and others. Combination drugs are further sub segmented into seretide/advair, symbicort, relvar/Breo ellipta, flutiform, dulera, and others.

Spiriva and others are sub segmentations of anticholinergics. Whereas, Inhaled corticosteroids are further sub segmented into pulmicort, flovent, qvar, and others. The global asthma and COPD drugs market is dominated by long term asthma control medications segment in the year 2023, capturing a notable market share of 71.4%. The dominance owes to the assistance of medications in preventing severe symptoms for a long period of time.

• Indacaterol Plus Mometasone, a novel fixed dose combination was launched by Glenmark, under the brand name Indamet, for patients suffering from uncontrollable asthma in India.

On the other hand, quick relief medications are further sub segmented into short acting beta agonists, ipratropium bromide (Atrovent), oral and intravenous corticosteroids, and others.

Route of Administration Analysis

Based on route of administration, the market fractionates into oral and inhaled route segments. Amongst these, oral route of administration segment dominates the market for asthma and COPD drugs grabbing a commendable market share of 65.8% in the year 2023. The segment being highly preferred is by virtue of high adoption rate in the form of tablets including Foradil and Symbicort, proving relief in shorter duration.

In addition, the segment is propelled robustly being least expensive, safe and convenient, thereby increasing its popularity in healthcare sectors. Oral medication is mostly preferred in case of acute asthma and especially for children where use of inhalers seems to be difficult.

Distribution Channel Analysis

Based on distribution channel, the market is bifurcated into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Drug Stores segments. Amonsgt all these, an instrumental role is played by retail pharmacies segment occupyring a major market share of 51.6% in the global asthma and COPD drugs market.

The segmental growth can be highly attributed to the increasing number of retail pharmacies helps in provision of appropriate drugs in comparison to hospital pharmacies in recent years. In majority of the cases, followed by prescription of medications by doctors, patients asthma and COPD usually prefer retail pharmacies to buy the related drugs along with repeat purchases.

• In United States, number of stores of top 10 retail pharmacies were around 31,053 in 2016.

Key Market Segments

By Disease type

• COPD
• Asthma

By Medication

• Long-term Asthma Control Medications
  • Combination Drugs
    • Seretide/Advair
    • Symbicort
    • Relvar/Breo Ellipta
    • Flutiform
    • Dulera
    • Others
  • Anticholinergics
    • Spiriva
    • Others
  • Inhaled Corticosteroids
    • Pulmicort
    • Flovent
    • Qvar
    • Others
• Quick-Relief Medications
  • Short-acting beta agonists
    • Ventolin
    • ProAir
    • Others
  • Ipratropium bromide (Atrovent)
  • Oral and Intravenous Corticosteroids
  • Others

By Route of Administration

• Inhaled
• Oral
• Others (Intravenous, Subcutaneous)

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacie

Market Drivers

Prevalence of Asthma and COPD

Global asthma and COPD market is majorly driven by increasing pervasiveness of asthma and chronic obstructive pulmonary disease across the globe. Forming a major disease burden, these diseases leads to declining quality of life and premature death among population. Measured by debility adapted life years, asthma stands at 24^th among leading causes of breathing with disability and 34^th as the leading cause of disease burden. Thus, the rising cases of asthma and COPD optimistically influences new therapeutics development coupled with escalating ultimatum for asthma and COPD therapeutics globally, thereby resulting in global market excellence.

• According to Asthma and Allergy Foundation of America in June 2020, 1 in 13 Americans suffered from asthma.
• According to Global Disease Burden in 2019, approximately 265 million individuals suffered from asthma in 2019.

Market Restraints

Availability of alternative treatments

Global asthma and COPD drugs market encounters hindrance due to the presence of alternative treatments for treating asthma and chronic obstructive pulmonary disease. The avalibility of non pharmacological options for COPD and asthma such as pulmonary rehabilitation or lifestyle changes can decline the need for medication therapies and thereby decrease market potential for pharmaceutical firms.

Product recalls

Another crucial factor hampering the market growth in recent years include product recalls. Complying with stringent regulatory guidelines and adoption of good manufacturing practices can greatly help to counterbalance the restraint.

• In September 2021, Perrigo Company Plc, recalled Albuterol inhaler, which is utilized to open the airways to treat asthma and other respiratory conditions, due to potential clogging of medical device.

Opportunities

Technological advancements and rising geriatric population offers growth opportunities

The global asthma and COPD drugs market is gaining lucrative opportunities by virtue of rising growth strategies including collaborations and partnerships. For instance, a partnership was established between Phil, Inc. a patient access platform company specializing in life science product commercialization and Teva Pharmaceutical Industries Ltd, an Israel based medical company with the aim to assist patients to receive and refill its Digihaler medication, by launching PhilRx Patient Access Platform.

Another factor contributing towards market success include rising geriatric population more necessitating respiratory illness medications. Advancements in technology coupled with new product launches is further triggering the market growth

• According to World Ageing 2020 estimate, in 2020, the global population was roughly 727 million people aged 65 and above and expected to hike till 1.5 billion by 2050.
• AstraZeneca, a well known pharmaceutical company received approval from European Union for its Trixeo Aerosphere for COPD supportive therapy in December 2020.

Latest Trends

Combination Therapies

The treatment and efficacy of asthma and COPD symptoms notably ameliorated with the formulation of combination therapies. The development of combination therapies include combining of different classes of medications, for example, corticosteroids and bronchodilators, results in a new improvised therapeutic medication.

Immunotherapy

Research and development efforts has led into formation of novel therapeutic options for diverse respiratory conditions. The ongoing research into immunotherapy approaches including anti-inflammatory therapies for COPD and allergen immunotherapy for asthma made ease in providing appropriate and safe medications for patients dealing with COPD and asthma.

Impact of Macroeconomic Factors

Globalization & Economy Likely to Influence Market Growth

Globalization in the form of international trade and supply chain dynamics highly influences the availability and pricing of asthma and COPD medications. The expense of asthma treatments in diverse market is affected by the changes occurring in trade policies, currency exchange rates and tariffs. In addition to these, the severity of asthma coupled with its prevalence is also influenced by environmental factors such as climate change, allergen exposure, and air pollution.

The hike in these concerns demands for advanced asthma and COPD treatments, especially in high pollution level containing regions. And lastly, growth in economy impacts the overall purchasing power of patients combined with healthcare spending capacity. Higher the economic growth, more is the inclination towards medical care including asthma and COPD treatment, thereby demanding medications, devices and healthcare services, leading to growth in market reach.

Regional Analysis

North America leads the global asthma and COPD market in the year 2023, capturing a valuable market share of 32.4%. The regional growth is highly ascribed rising cases of asthma and COPD, rising geriatric population, existence of well known market players and heightened research and development efforts in related field. Amongst these combination of factors, rising prevalence of asthma and COPD majorly boosts the market.

In addition to the aforementioned factors, another noteworthy factor fueling the market growth includes rising number of fundings by governmental and non-governmental organizations, leading to increasing awareness regarding asthma which in turn rises the adoption rate of asthma treatments. The region is leveraged with advanced healthcare infrastructure and presence of local pharmaceutical players emphasizing towards the development of novel therapeutic medications, further bolstering the regional growth in recent years.

• According to AAFA article published in September 2022, around 25 million people dealt with asthma in United States.
• According to National Institute of Health article published in March 2022, chronic obstructive pulmonary disorder affected more than 15 million adults in United States.
• United States Federal Health Programs in March 2022, issued a bill that involved the USD 8.5 billion for supporting CDC asthma programs. This included around the USD 30 million for National Asthma Control Program.

Key Regions and Countries

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Russia
  • Netherland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • New Zealand
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA

Key Players Analysis

Developing key players are concentrated on various strategies to develop their particular companies in foreign markets. Several Asthma and COPD market companies are concentrating on growing their R&D facilities and existing operations. Furthermore, businesses in the Asthma and COPD market are developing a portfolio and new product expansion strategies through mergers, investments, and acquisitions. In addition, numerous key players are now concentrating on different marketing strategies, such as increasing awareness about advanced features, which is expanding the growth of target products.

Market Key Players

With many local and regional players, the market for global Asthma and COPD is fragmented. Market players are subject to intense competition from top market players, particularly those with strong brand recognition and high distribution networks. Companies have gained various expansion strategies, such as partnerships and product launches, to stay on top of the market.

Listed below are some of the most prominent Asthma and COPD market players:

• GlaxoSmithKline Plc.
• AstraZeneca Plc.
• Novartis AG
• Merck and Co Inc.
• Teva Pharmaceutical Industries Ltd
• Sanofi
• Suvonion Pharmaceuticals, Inc.
• Roche Holdings AG
• Vectura Group
• Pfizer

Recent Developments

• In October 2021: Tiotropium Bromide dry powder inhaler was introduced by Glenmark Pharmaceutical under the trade name Tavulus in Spain for diagnosis of COPD.
• In April 2020: Cipla’s generic asthma inhaler, the generic counterpart of albuterol inhaler was approved by Food & Drug Administration. This medication is frequently used as a rescue medication for asthmatics.

Report Scope